

DAFTAR PUSTAKA

- American diabetes association (ADA), 2011 Standards of Medical Care in Diabetes—2011
- American diabetes association (ADA), 2013 executive summary: standars of medical care in diabetes -2013 diabetes jurnal S8
- American Diabetes association (ADA) 2013 Diagnosa dan Clasification of diabetes mellitus , diabetes care , volume 36, Suplement 1 , S67-S74.
- Aslam , M 2003 , Farmasi Klinik , PT Elex Media Komputindo , Jakarta .
- Badan POM RI , 2008, informatorium obat nasional Indonesia 2008, BPOM RI< Jakarta pp. 68-70
- Benet L, Hoener B. : Changers in Plasma Protein binding have little clinical relevance . Clin Pharmacol Ther 71 : 115-121, 2002
- Bennett , P. Epidemiology of type 2 Diabetes Mellitus . In Le Roith et . al , Diabetes Melitus a Fundamental and Clinical Text . Philadelphia : Lippincott William dan Wilkin S. 2008: 43 (1) : 554-7 .
- Bharti chogtu, Rahul Magazine, and KL Bairy , Statin use and risk of diabetes mellitus , Word J Diabetes, 2015 maret 6 (2): 352-357 diterbitkan online 2015 15 maret . Doi.104239/ wjd. V6. I2. 352 .”
- Depkes RI., 2005 ., Kumpulan Peraturan Perundang-undangan., Direktorat Jenderal Pengawasan Obat dan Makanan, Jakarta.
- Departeman kesehatan , Pharmaseutical care untuk penyakit diabetes mellitus , 2005
- Dipiro JT, dkk. 2005. Pharmacotherapy A Pathophysiologic Approach (6th ed.,). USA: McGraw-Hill Companies`
- Dipiro, Joseph T, et al, 2006. Pharmacotherapy Handbook, Sixth Edition, Mc Graw Hill Companies: Inc, New York, USA.
- Gunawan., Sulistia G., 2007. Farmakologi dan Terapi Edisi V., Departemen Farmakologi dan Terapeuti, EGC, Jakarta. Guyton Hall, 2009. Buku Ajar Fisiologi. Penerbit Buku Kedokteran, EGC. Jakarta.
- Goodman & Gilman. 2007. Dasar Farmakologi Terapi, Edisi 10, Vol 1. Penerbit Buku Kedokteran EGC. Jakarta.
- Goodman & Gilman. 2007. Dasar Farmakologi Terapi, Edisi 10, Vol 2. Penerbit Buku Kedokteran EGC. Jakarta Mansjoer, A., K. Triyanti., R. Savitri., W. I. Wardhani., dan W. Setiowulan., (Editor), 2000. Kapita Selekta Kedokteran, Edisi 3 jilid 1 Media Aesculapius., Fakultas Kedokteran Universitas Indonesia., Jakarta

- Harding , Anne Helen ey al. dietary Fat and Risk Of Clinial Type Diabetes Mellitus , American Journal of Efidemology . 2003 : 15 (1); 150 -9.
- Misnadiarly., 2006., Diabetes Melitus, Gangren, Ulcer, Infeksi, Pustaka Populer Obor., Jakarta.
- Perkeni ,2011, consensus pengelolaan dan pencegahan Diabetes Melitus Tipe 2 di Indonesia , Perkeni , Jakarta.
- Perhimpunan Peneliti Penyakit Tropik dan Infeksi (PETRI)., 2009., Compendium of Indonesian Medicine IPD 1 st Edition., Jakarta.
- Priyanto. 2009. Farmakoterapi dan Terminologi Medis. LESKONFI. Jakarta
- Piscitelli, SC., Rodvold, KA., 2002. Drug Interactions in Infectious Diseases, Humana Press Inc, Totowa, NJ.
- Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, JKjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D for The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 2011;32:1769-818.
- Shoback, edited by David G. Gardner, Dolores (2011). Greenspan's basic & clinical endocrinology (edisi ke-9th). New York: McGraw-Hill Medical. hlm. Chapter 17. ISBN 0-07-162243-8.*
- Stockley I., 2008. Drug Interaction A Source Book of Adserve Interaction, Their Mechanism, Clinical Importance and Management (8rd ed.), University of Nottingham Medical School., England.
- Sudoyo W.A, et al, editor. 2006. Buku Ajar ilmu Penyakit Dalam. Jilid 3. Edisi IV, Penerbit Fakultas Kedokteran Universitas Indonesia, Jakarta.
- Soegondo S., 2008, "Diabetes, The Silent Killer", at <http://www.medicastore.com>., Bagian Metabolik dan Endokrin., FKUI/RSCM., Jakarta., akses 20 mei 2012.
- Sutedjo , A.Y., 2009 buku saku mengenal penyakit melalui hasil pemeriksaan laboratorium , Amara Books , Yogyakarta , PP 114-116.
- Tatro , .D.S 2009 , Drug Interaction Facts . Facts and Comporation Publising Grup , San Carlos , California .
- Vijan, S (2010-03-02). "Type 2 diabetes". *Annals of internal medicine*. **152** (5): ITC31–15; quiz ITC316. doi:[10.1059/0003-4819-152-5-201003020-01003](https://doi.org/10.1059/0003-4819-152-5-201003020-01003). PMID [20194231](https://pubmed.ncbi.nlm.nih.gov/20194231/).

Waspanji S. kaki diabetes . Dalam : sudoyono AW, Setiyohadi B , Alwi I, Simadibrata M, Setiati S, editors . Buku ajar ilmu penyakit dalam , jilid III, edisi ke lima , Jakarta : Interna Publisng , 2009.h. 1961.

Williams textbook of endocrinology (edisi ke-12th). Philadelphia: Elsevier/Saunders. hlm. 1371–1435. [ISBN 978-1-4377-0324-5](#)

Yeni Farida dan Claudia Putri' Efek simvastatin terhadap kenaikan gula darah puasanpasien diabetes mellitus tipe 2" I.P Fmipa Jurusan farmasi Universitas Sebelas Maret Surakarta tahun 2016.

Lampiran

Tabel 6. Korelasi Nilai GDP dan Lama Derita DM

Variabel	Metformin + Simvastatin						Glimepiride+ Simvastatin						Metformin + Glimepiride + Simvastatin					
	1		2		3		1		2		3		1		2		3	
	r	p	r	p	R	p	r	p	r	p	r	p	r	p	r	p	r	p
GDP	-		-		-		0,2	0,3	0,1	0,5	0,0	0,8	0,1	0,7	0,3	0,1	0,2	0,2
La	0,1	0,5	0,1	0,4	0,1	0,4	0,2	0,3	0,1	0,5	0,0	0,8	0,1	0,7	0,3	0,1	0,2	0,2
De	1	04	24	51	17	79	68	76	85	44	77	01	06	61	13	05	26	48
rita																		
D																		
1																		
M																		

Koefisien (nilai r)	Kekuatan Hubungan
0,00	Tidak ada hubungan
0,01 – 0,09	Hubungan kurang berarti
0,10 – 0,29	Hubungan lemah
0,30 – 0,49	Hubungan moderat
0,50 – 0,69	Hubungan kuat
0,70 – 0,89	Hubungan sangat kuat
>0,90	Hubungan mendekati sempurna

Jika negatif berarti hubungan tidak searah, jika positif berarti hubungan searah

Lampiran uji statistika

Jenis kelamin

	Frequency	Percent	Valid Percent	Cumulative Percent
Laki-laki	23	28.8	28.8	28.8
Valid Perempuan	57	71.3	71.3	100.0
Total	80	100.0	100.0	

UMUR

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid 23-37 Tahun	1	1.3	1.3	1.3

Lampiran uji statistika

Jenis kelamin

	Frequency	Percent	Valid Percent	Cumulative Percent
Laki-laki	23	28.8	28.8	28.8
Valid Perempuan	57	71.3	71.3	100.0
Total	80	100.0	100.0	

UMUR

	Frequency	Percent	Valid Percent	Cumulative Percent
23-37 Tahun	1	1.3	1.3	1.3
38-52 Tahun	9	11.3	11.3	12.5
Valid 53-67 Tahun	58	72.5	72.5	85.0
68-82 Tahun	12	15.0	15.0	100.0
Total	80	100.0	100.0	

IMT

	Frequency	Percent	Valid Percent	Cumulative Percent
Under Weight	1	1.3	1.3	1.3
Normal	15	18.8	18.8	20.0
Valid Risiko Obesitas	25	31.3	31.3	51.3
Obese 1	37	46.3	46.3	97.5
obese 2	2	2.5	2.5	100.0
Total	80	100.0	100.0	

Lama Durasi obat

	Frequency	Percent	Valid Percent	Cumulative Percent
Dibawah sama dengan 1 Tahun	16	20.0	20.0	20.0
Valid 2-5 Tahun	58	72.5	72.5	92.5
6-10 Tahun	6	7.5	7.5	100.0
Total	80	100.0	100.0	

Descriptives

			Statistic	Std. Error
GDP bulan ke-1 (Glimepirid)	Mean		202.2308	24.30579
	95% Confidence Interval for Mean	Lower Bound	149.2730	
		Upper Bound	255.1885	
	5% Trimmed Mean		196.4786	
	Median		204.0000	
	Variance		7680.026	
	Std. Deviation		87.63576	
	Minimum		94.00	
	Maximum		414.00	
	Range		320.00	
	Interquartile Range		122.50	
	Skewness		1.060	.616
	Kurtosis		1.654	1.191
GDP bulan ke-2 (Glimepirid)	Mean		198.2308	20.77880
	95% Confidence Interval for Mean	Lower Bound	152.9577	
		Upper Bound	243.5039	
	5% Trimmed Mean		195.8120	
	Median		172.0000	
	Variance		5612.859	
	Std. Deviation		74.91902	
	Minimum		100.00	
	Maximum		340.00	
	Range		240.00	
	Interquartile Range		95.00	
	Skewness		.663	.616
	Kurtosis		-.141	1.191
GDP bulan ke-3 (Glimepirid)	Mean		179.5385	19.66306
	95% Confidence Interval for Mean	Lower Bound	136.6963	
		Upper Bound	222.3806	
	5% Trimmed Mean		175.5427	
	Median		171.0000	
	Variance		5026.269	
	Std. Deviation		70.89619	
	Minimum		87.00	
	Maximum		344.00	

Range	257.00	
Interquartile Range	100.00	
Skewness	.971	.616
Kurtosis	1.083	1.191

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
GDP bulan ke-1 (Glimepirid)	.162	13	.200 [*]	.921	13	.262
GDP bulan ke-2 (Glimepirid)	.175	13	.200 [*]	.930	13	.337
GDP bulan ke-3 (Glimepirid)	.130	13	.200 [*]	.933	13	.368

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Descriptives

		Statistic	Std. Error	
GDP bulan ke 1 (Metformin+Glimepirid)	Mean	238.5000	15.40112	
	95% Confidence Interval for Mean	Lower Bound	206.8995	
		Upper Bound	270.1005	
	5% Trimmed Mean	233.6032		
	Median	222.5000		
	Variance	6641.444		
	Std. Deviation	81.49506		
	Minimum	100.00		
	Maximum	486.00		
	Range	386.00		
	Interquartile Range	96.00		
	Skewness	1.121	.441	
	Kurtosis	1.917	.858	
	GDP bulan ke-2 (Metformin+Glimepirid)	Mean	210.1786	10.03763
95% Confidence Interval for Mean		Lower Bound	189.5830	
		Upper Bound	230.7741	
5% Trimmed Mean		209.5556		
Median	202.5000			
Variance	2821.115			
Std. Deviation	53.11417			

	Minimum		108.00	
	Maximum		327.00	
	Range		219.00	
	Interquartile Range		75.25	
	Skewness		.221	.441
	Kurtosis		-.319	.858
	Mean		194.7143	10.93038
	95% Confidence Interval for Mean	Lower Bound	172.2870	
		Upper Bound	217.1416	
	5% Trimmed Mean		193.1667	
	Median		194.0000	
	Variance		3345.249	
GDP bulan ke-3 (Metformin+ Glimepirid)	Std. Deviation		57.83812	
	Minimum		97.00	
	Maximum		322.00	
	Range		225.00	
	Interquartile Range		93.25	
	Skewness		.307	.441
	Kurtosis		-.508	.858

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
GDP bulan ke 1 (Metformin+Glimepirid)	.118	28	.200*	.932	28	.071
GDP bulan ke-2 (Metformin+Glimepirid)	.124	28	.200*	.986	28	.957
GDP bulan ke-3 (Metformin+ Glimepirid)	.112	28	.200*	.974	28	.696

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Descriptives

	Statistic	Std. Error
Mean	253,5641	10,07769
95% Confidence Interval for Lower Bound	233,1629	
Mean Upper Bound	273,9653	
Bulan Ke 1 Kelompok 5% Trimmed Mean	251,3875	
Metformin tanpa simvastatin Median	246,0000	
Variance	3960,831	
Std. Deviation	62,93514	
Minimum	134,00	

Bulan ke 2 kelompok Metformin + simvastatin	Maximum	462,00	
	Range	328,00	
	Interquartile Range	80,00	
	Skewness	,633	,378
	Kurtosis	1,927	,741
	Mean	195,8974	7,46298
	95% Confidence Interval for Lower Bound	180,7894	
	Mean	Upper Bound	211,0055
	5% Trimmed Mean	193,4060	
	Median	180,0000	
	Variance	2172,147	
	Std. Deviation	46,60630	
	Minimum	120,00	
	Maximum	341,00	
	Range	221,00	
Bulan ke 3 kelompok metformin + simvastatin	Interquartile Range	79,00	
	Skewness	,876	,378
	Kurtosis	,751	,741
	Mean	158,2051	5,99327
	95% Confidence Interval for Lower Bound	146,0724	
	Mean	Upper Bound	170,3379
	5% Trimmed Mean	157,6581	
	Median	146,0000	
	Variance	1400,852	
	Std. Deviation	37,42795	
	Minimum	88,00	
	Maximum	248,00	
	Range	160,00	
	Interquartile Range	74,00	
	Skewness	,394	,378
Kurtosis	-,618	,741	

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	Df	Sig.	Statistic	df	Sig.
Bulan Ke 1 Kelompok Metformin + simvastatin	,082	39	,200*	,957	39	,144

Bulan ke 2 kelompok Metformin tanpa simvastatin	,181	39	,002	,917	39	,007
Bulan ke 3 kelompok metformin tanpa simvastatin	,141	39	,050	,951	39	,089

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Descriptives

		Statistic	Std. Error
Bulan Ke 1 Kelompok Glimepiride simvastatin	Mean	271,1538	24,10816
	95% Confidence Interval for Lower Bound	218,6267	
	Mean	Upper Bound	323,6810
	5% Trimmed Mean	268,8376	
	Median	266,0000	
	Variance	7555,641	
	Std. Deviation	86,92319	
	Minimum	122,00	
	Maximum	462,00	
	Range	340,00	
	Interquartile Range	102,00	
	Skewness	,606	,616
	Kurtosis	1,060	1,191
	Mean	259,5385	23,03192
95% Confidence Interval for Lower Bound	209,3562		
Mean	Upper Bound	309,7207	
5% Trimmed Mean	253,1538		
Median	242,0000		
Bulan ke 2 kelompok Glimepiride simvastatin	Variance	6896,103	
	Std. Deviation	83,04278	
	Minimum	172,00	
	Maximum	462,00	
	Range	290,00	
	Interquartile Range	92,00	
	Skewness	1,481	,616
	Kurtosis	1,946	1,191
Bulan ke 3 kelompok Glimepiride simvastatin	Mean	211,6154	14,17633
	95% Confidence Interval for Lower Bound	180,7278	
	Mean	Upper Bound	242,5030
	5% Trimmed Mean	212,7949	

Median	210,0000	
Variance	2612,590	
Std. Deviation	51,11350	
Minimum	114,00	
Maximum	288,00	
Range	174,00	
Interquartile Range	55,50	
Skewness	-,711	,616
Kurtosis	,311	1,191

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	Df	Sig.	Statistic	df	Sig.
Bulan Ke 1 Kelompok Glimepiride + simvastatin	,138	13	,200*	,969	13	,878
Bulan ke 2 kelompok Glimepiride + simvastatin	,180	13	,200*	,855	13	,033
Bulan ke 3 kelompok Glimepiride + simvastatin	,182	13	,200*	,927	13	,307

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Descriptives

	Statistic	Std. Error
Mean	259,5714	8,15596
95% Confidence Interval for Lower Bound	242,8368	
Mean Upper Bound	276,3061	
5% Trimmed Mean	260,1349	
Bulan Ke 1 Kelompok Kombinasi (Metformin + Glimepiride) + simvastatin	Median	247,0000
	Variance	1862,550
	Std. Deviation	43,15727
	Minimum	168,00
	Maximum	341,00
	Range	173,00
	Interquartile Range	51,75
	Skewness	,028
		,441

Bulan ke 2 kelompok kombinasi (Metformin + Glimpiride) simvastatin	Kurtosis	-,317	,858	
	Mean	203,6786	8,43604	
	95% Confidence Interval for Lower Bound	186,3692		
	Mean	Upper Bound	220,9879	
	5% Trimmed Mean	200,8651		
	Median	200,0000		
	Variance	1992,671		
	Std. Deviation	44,63934		
	Minimum	146,00		
	Maximum	320,00		
	Range	174,00		
	Interquartile Range	70,25		
	Skewness	,960	,441	
	Kurtosis	,542	,858	
	Mean	161,7500	8,96917	
	95% Confidence Interval for Lower Bound	143,3468		
	Mean	Upper Bound	180,1532	
5% Trimmed Mean	159,7063			
Median	146,5000			
Variance	2252,491			
Std. Deviation	47,46041			
Minimum	102,00			
Maximum	260,00			
Range	158,00			
Interquartile Range	81,50			
Skewness	,612	,441		
Kurtosis	-,796	,858		

Tests of Normality

	Kolmogorov-Smimov ^a			Shapiro-Wilk		
	Statistic	Df	Sig.	Statistic	df	Sig.
Bulan Ke 1 Kelompok Kombinasi (Metformin + Glimpiride) simvastatin	,141	28	,160	,966	28	,484
Bulan ke 2 kelompok kombinasi (Metformin + Glimpiride) simvastatin	,140	28	,168	,918	28	,031

Bulan ke 3 kelompok kombinasi (Metformin + Glimpiride) tanpa simvastatin	,172	28	,033	,913	28	,023
--	------	----	------	------	----	------

a. Lilliefors Significance Correction

Uji repeated anova kelompok metformin

Tests of Within-Subjects Effects

Measure: MEASURE_1

Source	Type III Sum of Squares	df	Mean Square	F	Sig.	
GDP	Sphericity Assumed	4023.436	2	2011.718	.996	.374
	Greenhouse-Geisser	4023.436	1.676	2400.113	.996	.363
	Huynh-Feldt	4023.436	1.745	2305.949	.996	.365
	Lower-bound	4023.436	1.000	4023.436	.996	.325
Error(GDP)	Sphericity Assumed	153547.231	76	2020.358		
	Greenhouse-Geisser	153547.231	63.701	2410.422		
	Huynh-Feldt	153547.231	66.303	2315.853		
	Lower-bound	153547.231	38.000	4040.717		

Uji repeated anova kelompok glimepirid

Tests of Within-Subjects Effects

Measure: Obat

Source	Type III Sum of Squares	df	Mean Square	F	Sig.	
GDP	Sphericity Assumed	3814.821	2	1907.410	1.106	.347
	Greenhouse-Geisser	3814.821	1.906	2001.727	1.106	.345
	Huynh-Feldt	3814.821	2.000	1907.410	1.106	.347
	Lower-bound	3814.821	1.000	3814.821	1.106	.314
Error(GDP)	Sphericity Assumed	41393.179	24	1724.716		
	Greenhouse-Geisser	41393.179	22.869	1809.999		
	Huynh-Feldt	41393.179	24.000	1724.716		
	Lower-bound	41393.179	12.000	3449.432		